Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maat PharmaFRA:4RD +2.07%27 PB Ratio is 28.23 as of Jul. 25, 2026, which is 590% above its 10-year median of 4.09. GuruFocus rates FRA:4RD with a GF Score™ of 27/100 and a GF Value™ of €10.64 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Maat Pharma ranks worse than 95.52% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-25), Maat Pharma's share price is €2.71. Maat Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was €0.10. Hence, Maat Pharma's PB Ratio of today is 28.23.
The historical rank and industry rank for Maat Pharma's PB Ratio or its related term are showing as below:
FRA:4RD'
s PB Ratio Range Over the Past 10 Years
Min: 1.93 Med: 4.09 Max: 81.04
Current: 27.71
During the past 8 years, Maat Pharma's highest PB Ratio was 81.04. The lowest was 1.93. And the median was 4.09.
FRA:4RD's PB Ratio is ranked worse than 95.52% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs FRA:4RD: 27.71
During the past 12 months, Maat Pharma's average Book Value Per Share Growth Rate was -87.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -67.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -43.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Maat Pharma was 211.80% per year. The lowest was -67.10% per year. And the median was -20.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Maat Pharma PB Ratio Related Terms
Maat Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Maat Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maat Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maat Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maat Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Maat Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Maat Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Maat Pharma (FRA:4RD) has a PB Ratio of 28.23 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Maat Pharma and its competitors. This is 590% above median its historical median of 4.09. Over the past decade, Maat Pharma's PB Ratio has ranged from 1.93 to 81.04. According to the industry distribution chart, Maat Pharma ranks #1174 out of 1229 companies in the Biotechnology industry, placing it in the top 95.5%.
Is Maat Pharma's PB Ratio too high?
Maat Pharma's current PB Ratio of 28.23 is 590% above median its 10-year median of 4.09. Over the past 10 years, this metric has ranged from a low of 1.93 to a high of 81.04. The Biotechnology industry median PB Ratio is 2.79. Maat Pharma's value of 28.23 is 911.8% above this industry median. Based on the distribution chart, Maat Pharma ranks #1174 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #1174 out of 1229 companies for PB Ratio. This places Maat Pharma in the lower half of its industry. The industry median PB Ratio is 2.79. Maat Pharma's value of 28.23 is 911.8% above this benchmark. Historically, Maat Pharma's own PB Ratio has ranged from 1.93 to 81.04 over the past decade. While the company's 10-year median is 4.09 vs. the industry median of 2.79, Maat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maat Pharma's current PB Ratio of 28.23 is 911.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Maat Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maat Pharma's current PB Ratio is 28.23, which is 590% above median its own 10-year median of 4.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (FRA:4RD) is currently considered Possible Value Trap. The stock's GF Value™ is €10.64, compared to a current price of €2.71 — trading 74.5% below its estimated fair value. The current PB Ratio is 28.23, which is 590% above median its 10-year median of 4.09 and 911.8% above the Biotechnology industry median of 2.79. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Maat Pharma (FRA:4RD), the current PB Ratio is 28.23 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maat Pharma (FRA:4RD) Overvalued in 2026?
Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued.
The current stock price of €2.71 is trading 74.5% below its estimated GF Value™ of €10.64.
GuruFocus considers Maat Pharma to be Possible Value Trap.
Key valuation signals for FRA:4RD:
PB Ratio: 28.23 (590% above median its 10-year median of 4.09)
GF Value™: €10.64 vs. price of €2.71 (74.5% below fair value)
Industry Position: 911.8% above the Biotechnology median (#1174 of 1229)
No single metric tells the full story. See the FRA:4RD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score
Get the complete analysis for FRA:4RD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RD has been successfully added to your 
